Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 4/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906363 | 0.80 | GRN (0.39) | GRNSORT1KDM4EALDH1A1NPC1 | |
| SCHEMBL12847484 | 0.78 | GRN (0.35) | GRNSORT1KDM4EALDH1A1NPC1 | |
| SCHEMBL9906364 | 0.77 | CNR1 (0.43) | GRNSORT1KDM4EALDH1A1NPC1 | |
| SCHEMBL13114437 | 0.75 | CNR1 (0.41) | GRNSORT1KDM4EALDH1A1NPC1 | |
| SCHEMBL12789841 | 0.75 | GRN (0.36) | GRNSORT1KDM4EALDH1A1NPC1 | |
| SCHEMBL9908245 | 0.75 | MAPK14 (0.39) | GRNSORT1KDM4EALDH1A1NPC1 | |
| SCHEMBL1133872 | 0.75 | GRN (0.59) | GRNSORT1KDM4EALDH1A1NPC1 | |
| SCHEMBL12789845 | 0.74 | GRN (0.37) | GRNSORT1KDM4EALDH1A1CNR1 | |
| SCHEMBL12789852 | 0.74 | GRN (0.35) | GRNSORT1KDM4EALDH1A1NPC1 | |
| SCHEMBL12789842 | 0.73 | CRHR1 (0.39) | GRNSORT1ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | BRAF, NRAS, ARAF | GRN 3128/4885SORT1 3257/4885KDM4E 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.